To the best of our knowledge, this study was the largest to evaluate the clinical utility of plasma EGFR mutation analysis in treatment-naïve stage IV NSCLC, and the first to report an association between serum CEA levels and a positive plasma EGFR mutation test result. This evidence concerns the gene EGFR and non-small cell lung carcinoma.